2021
Interplay between RNA Methylation Eraser FTO and Writer METTL3 in Renal Clear Cell Carcinoma Patient Survival
Zhao J, Lu L. Interplay between RNA Methylation Eraser FTO and Writer METTL3 in Renal Clear Cell Carcinoma Patient Survival. Recent Patents On Anti-Cancer Drug Discovery 2021, 16: 363-376. PMID: 33563180, DOI: 10.2174/1574892816666210204125155.Peer-Reviewed Original ResearchConceptsMETTL3 mRNASurvival analysisFTO mRNAKaplan-Meier survival curvesAdjusted hazard ratioMultivariate Cox regressionRenal clear cell carcinomaClear cell carcinomaInflammation-related genesPotential prognostic markerM6A methyltransferase METTL3Upregulation of FTOHazard ratioCox regressionPatient survivalPrognostic valueCell carcinomaPrognostic markerSuperior survivalImmune responseMETTL3 expressionDifferential expressionClinical relevanceLower DNA methylationSurvival curves
2020
Regulation and characterization of tumor-infiltrating immune cells in breast cancer
Dai Q, Wu W, Amei A, Yan X, Lu L, Wang Z. Regulation and characterization of tumor-infiltrating immune cells in breast cancer. International Immunopharmacology 2020, 90: 107167. PMID: 33223469, PMCID: PMC7855363, DOI: 10.1016/j.intimp.2020.107167.Peer-Reviewed Original ResearchConceptsTumor-infiltrating immune cellsT cell activation statusImmune cellsCell activation statusT cell activationPatient survivalM2 macrophagesT cellsBreast cancerCell activationT cell peripheral toleranceTumor-infiltrating B cellsMultivariate Cox regression modelActivation statusBreast cancer patient survivalEffector T cellsT cell subsetsBreast cancer patientsImmune cell infiltrationAbundant plasma cellsCox regression modelKaplan-Meier survivalImmune cell typesMolecular pathwaysCancer patient survivalSyndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer.
Wu Y, Huang H, Fervers B, Lu L. Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer. Pancreas 2020, 49: 1187-1194. PMID: 32898003, DOI: 10.1097/mpa.0000000000001654.Peer-Reviewed Original ResearchConceptsSyndecan-1Patient survivalPancreatic cancerAdjusted hazard ratioPancreatic cancer patientsKRAS somatic mutationsSDC1 mRNASomatic mutationsHazard ratioCancer patientsClinical dataSurvival analysisKRASPatientsKyoto EncyclopediaKRAS mRNAElevated mortalityGenomes (KEGG) pathway analysisCancerPathway analysisLower methylationMolecular characteristicsSurvivalMRNANegative correlation
2019
Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma
Lu L, Gaffney SG, Cannataro VL, Townsend J. Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma. Oral Oncology 2019, 101: 104554. PMID: 31887619, PMCID: PMC7273869, DOI: 10.1016/j.oraloncology.2019.104554.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkersFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateLymphocyte ActivationMaleMethyltransferasesMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisProportional Hazards ModelsSquamous Cell Carcinoma of Head and NeckT-LymphocytesYoung AdultConceptsT cell activation scoreT cell activation statusAdjusted hazard ratioPatient survivalHPV statusHazard ratioActivation statusActivation scoresKaplan-Meier survival curvesImmune checkpoint blockadeCox regression modelNeck squamous carcinomaPotential therapeutic targetT cell activationHNSCC patientsSquamous carcinomaPatient mortalityLonger survivalExhaustion groupsTherapeutic targetSurvival curvesSignificant associationMRNA expressionPatientsSurvival
2018
High tRNA Transferase NSUN2 Gene Expression is Associated with Poor Prognosis in Head and Neck Squamous Carcinoma
Lu L, Zhu G, Zeng H, Xu Q, Holzmann K. High tRNA Transferase NSUN2 Gene Expression is Associated with Poor Prognosis in Head and Neck Squamous Carcinoma. Cancer Investigation 2018, 36: 246-253. PMID: 29775108, DOI: 10.1080/07357907.2018.1466896.Peer-Reviewed Original ResearchConceptsPotential independent prognostic markerShorter overall survivalIndependent prognostic markerHigher mortality riskNeck squamous carcinomaPotential therapeutic targetRandom-effects modelOverall survivalSquamous carcinomaPoor prognosisPrognostic valuePrognostic markerMortality riskTherapeutic targetHNSCCNormal tissuesCell developmentExpressionGene expressionRNA methylationPatientsCarcinomaPrognosisNSUN2Important role
2017
Elevated T cell activation score is associated with improved survival of breast cancer
Lu L, Bai Y, Wang Z. Elevated T cell activation score is associated with improved survival of breast cancer. Breast Cancer Research And Treatment 2017, 164: 689-696. PMID: 28488141, DOI: 10.1007/s10549-017-4281-x.Peer-Reviewed Original ResearchConceptsT cell activation scoreBreast cancer patientsOverall survivalPatients' overall survivalCancer patientsImproved survivalPD-1Activation scoresBreast cancerCell death-1 receptorLow PD-1 expressionMultivariate Cox regression analysisT-lymphocyte antigen-4Kaplan-Meier survival curvesT cell activation statusDeath-1 receptorPD-1 expressionEffector T cellsImmune checkpoint blockadeCox regression analysisPoor overall survivalCox regression modelT cell functionActivation groupCell activation status
2016
Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer
Deloria AJ, Höflmayer D, Kienzl P, Łopatecka J, Sampl S, Klimpfinger M, Braunschmid T, Bastian F, Lu L, Marian B, Stättner S, Holzmann K. Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer. Oncotarget 2016, 5: 73800-73816. PMID: 27650542, PMCID: PMC5342015, DOI: 10.18632/oncotarget.12070.Peer-Reviewed Original ResearchConceptsColorectal cancerEpithelial-mesenchymal transitionPrognostic valueNon-neoplastic colorectal epitheliumPrognosis of CRCFavorable overall survivalHuman colorectal cancerRole of ESRP1Overall survivalCRC casesPathological stageCRC cellsPrognostic stratificationFavorable outcomeTumor stagingClinical dataTCGA cohortColorectal epitheliumTumor progressionMicrosatellite instabilityMicrosatellite stabilityTumor cellsEarly detectionProtein 1Tissue expression
2015
Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis
Wang Z, Katsaros D, Shen Y, Fu Y, Canuto EM, Benedetto C, Lu L, Chu WM, Risch HA, Yu H. Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis. PLOS ONE 2015, 10: e0136246. PMID: 26287798, PMCID: PMC4546117, DOI: 10.1371/journal.pone.0136246.Peer-Reviewed Original ResearchConceptsBreast cancer prognosisCancer prognosisGene expression signaturesExpression signaturesPoor disease-free survivalDisease-free survivalBreast cancer patientsBreast cancer cell linesBreast cancer progressionMDA-MB-468Tumor cell growthMDA-MB-231Multiple gene expression signaturesCancer cell linesAggressive tumorsCancer patientsClinical significanceDisease outcomeTumor featuresClinical implicationsPrognosisCancer progressionBiologic relevanceHigh expressionCell proliferationMicroRNA let‐7a modifies the effect of self‐renewal gene HIWI on patient survival of epithelial ovarian cancer
Lu L, Katsaros D, Risch HA, Canuto EM, Biglia N, Yu H. MicroRNA let‐7a modifies the effect of self‐renewal gene HIWI on patient survival of epithelial ovarian cancer. Molecular Carcinogenesis 2015, 55: 357-365. PMID: 25630839, DOI: 10.1002/mc.22285.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerKaplan-Meier survival curvesOverall survivalHIWI expressionLet-7a expressionPatient survivalLet-7aClinical relevanceMultivariate Cox proportional hazards regression analysisCox proportional hazards regression analysisCox proportional hazards regression modelSurvival curvesProportional hazards regression analysisProportional hazards regression modelsLow let-7aHazards regression analysisRisk of deathPoor overall survivalHazards regression modelsMiRNA let-7aPrimary EOC tissuesQuantitative reverse transcription PCRU-shape associationEOC prognosisPrognostic significance
2013
An insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival
Lu L, Risch E, Deng Q, Biglia N, Picardo E, Katsaros D, Yu H. An insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival. Carcinogenesis 2013, 34: 2024-2030. PMID: 23677070, DOI: 10.1093/carcin/bgt168.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor IIIGF-II expressionPatient survivalGrowth factor IIPresence of carboplatinChemotherapy responseOvarian cancerCox proportional hazards regression modelKaplan-Meier survival curvesProportional hazards regression modelsFactor IIOvarian cancer tissue samplesIGF-II genotypeAdjusted hazard ratioOvarian cancer survivalHazards regression modelsCommercial enzyme-linked immunosorbentQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionOvarian cancer developmentTranscription-polymerase chain reactionCancer tissue samplesEnzyme-linked immunosorbentHazard ratioSNP genotyping assays
2012
Favorable outcome associated with an IGF-1 ligand signature in breast cancer
Mu L, Tuck D, Katsaros D, Lu L, Schulz V, Perincheri S, Menato G, Scarampi L, Harris L, Yu H. Favorable outcome associated with an IGF-1 ligand signature in breast cancer. Breast Cancer Research And Treatment 2012, 133: 321-331. PMID: 22297468, DOI: 10.1007/s10549-012-1952-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCohort StudiesDisease-Free SurvivalFemaleGene ExpressionGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansInsulin-Like Growth Factor Binding ProteinsInsulin-Like Growth Factor IKaplan-Meier EstimateLigandsMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalOligonucleotide Array Sequence AnalysisPrognosisReceptor, IGF Type 1Young AdultConceptsIGF-1 ligandBreast cancerFavorable outcomeInsulin-like growth factor (IGF) axisActivation signaturePrimary breast cancerGrowth factor axisPredictors of responseHuman breast cancerPathway analysisUpregulation of pathwaysBetter prognosisIGF axisPrognostic valueReceptor levelsLevels of mRNAFactor axisIGF ligandsIngenuity softwarePathway activation scoresCancerLigand levelsActivation scoresHigh groupProliferation pathways
2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011, 31: 4559-4566. PMID: 22139083, PMCID: PMC3342446, DOI: 10.1038/onc.2011.539.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCarboplatinCell Line, TumorCell SurvivalDrug Resistance, NeoplasmFemaleGenotypeHumansKaplan-Meier EstimateMiddle AgedMultivariate AnalysisMutationNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPolymorphism, Single NucleotidePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRNA InterferenceTreatment OutcomeConceptsEpithelial ovarian cancerEOC patientsKRAS-variantOvarian cancerPoor outcomeCancer riskTumor biologyPlatinum resistanceComplete clinical dataBiomarkers of outcomeDirect targetingEOC cell growthKnown BRCA mutationsFuture treatment approachesSubset of tumorsPlatinum chemotherapy resistanceCell linesNeoadjuvant chemotherapyBRCA mutationsClinical dataTreatment approachesChemotherapy resistanceKRAS oncogeneMultivariate analysisPatientsPhysical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1
Zeng H, Irwin ML, Lu L, Risch H, Mayne S, Mu L, Deng Q, Scarampi L, Mitidieri M, Katsaros D, Yu H. Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1. Breast Cancer Research And Treatment 2011, 133: 127-135. PMID: 21837478, DOI: 10.1007/s10549-011-1716-7.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChromosomal Proteins, Non-HistoneDNA MethylationEpigenesis, GeneticFemaleGene ExpressionGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansKaplan-Meier EstimateMotor ActivityRepressor ProteinsTumor Suppressor ProteinsConceptsBreast cancer patientsBreast cancer survivalCancer patientsPhysical activityOverall survivalSurvival outcomesTumor suppressor geneCancer survivalHormone receptor-positive tumorsModerate-intensity aerobic exerciseHigh expressionBreast cancer deathsReceptor-positive tumorsRandomized clinical trialsExercise-related changesSuppressor genePeripheral blood leukocytesBreast cancer diagnosisGene expressionDisease recurrenceAerobic exerciseCancer deathClinical trialsTumor featuresBlood leukocytes
2008
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Research And Treatment 2008, 117: 131-140. PMID: 18932017, DOI: 10.1007/s10549-008-0219-7.Peer-Reviewed Original ResearchConceptsMiR-21 expressionPoor disease-free survivalHigh miR-21 expressionDisease-free survivalHormone receptor statusHigh miR-21Breast cancerMiR-21Tumor samplesReceptor statusTumor gradeTGF-β1Elevated miR-21 expressionNegative hormone receptor statusProportional hazards regression analysisHigher TGF-β1Lymph node involvementEarly-stage diseaseEarly-stage patientsPrimary breast cancerHazards regression analysisHigh tumor gradeFresh tumor samplesTumor cell growthNode involvement